echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > BeiGene's Tislelizumab Approved for the Eighth Indication for Esophageal Squamous Cell Carcinoma

    BeiGene's Tislelizumab Approved for the Eighth Indication for Esophageal Squamous Cell Carcinoma

    • Last Update: 2022-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, the NMPA official website announced the latest announcement that BeiGene's anti-PD-1 antibody tislelizumab (Baizean) has been approved for a new indication


    Screenshot source: NMPA official website

    Tislelizumab is a humanized IgG4 anti-programmed death 1 (PD-1) monoclonal antibody designed to minimize binding to Fcγ receptors in macrophages


    Previously, tislelizumab has been approved for 7 indications in China, including full approval for: 1) in combination with chemotherapy for the treatment of patients with first-line advanced squamous non-small cell lung cancer (NSCLC); 2) in combination with chemotherapy For the treatment of first-line advanced non-squamous NSCLC patients; 3) for the treatment of second- or third-line locally advanced or metastatic NSCLC patients with disease progression after previous platinum-containing chemotherapy


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.